Encephalomalacia/gliosis, deep venous thrombosis, and cancer in Arg393His antithrombin Hanoi and the potential impact of the β-amyloid precursor protein (APP) on thrombosis and cancer

Abstract

<abstract> <p>A heterozygous Arg393His point mutation at the reactive site of antithrombin (AT) gene causing thrombosis in a Vietnamese patient is reported and named as Arg393His in AT-Hanoi. The present variant is characterized by a severe reduction of functionally active AT plasma concentration to 42% of normal resulting in multiple severe thrombotic events such as cerebral venous thrombosis (CVT) (encephalomalacia/gliosis), recurrent deep venous thrombosis (DVT) and the development of kidney cancer. Today the complexity of thrombophilia has grown with appreciation that multiple inherited and acquired risk factors may interact to result in a clinically thrombotic phenotype. This article focuses on the following issues: (1) pathophysiology and clinical conditions of Arg393His in AT-Hanoi; (2) “two way association” between cancer and thrombosis in which venous thromboembolism (VTE) can be both a presenting sign and a complication of cancer; (3) efficacy of anticoagulants used for the prevention of cancer-related thrombosis; (4) conditions of acquired risk factors such as cancer or genetic disorders via epigenetic modifications in gene-gene (epistasis) and/or gene-environment interactions such as in Lesch-Nyhan disease (LND), in which the β-amyloid precursor protein (APP) that may interact to predispose a patient to thrombosis and cancer. It is also necessary to study the hypoxanthine-guanine phosphoribosyltransferase (HGprt) enzyme, AT, and APP using expression vectors for exploring their impact on LND, thrombosis as well as other human diseases, especially the ones related to APP such as Alzheimer's disease (AD) and cancer. For such a purpose, the construction of expression vectors for HGprt and APP, with or without the glycosyl-phosphatidylinositol (GPI) anchor, was performed as described in Ref. #148 (Nguyen, K. V., Naviaux, R. K., Nyhan, W. L. Lesch-Nyhan disease: I. Construction of expression vectors for hypoxanthine-guanine phosphoribosyltransferase (HGprt) enzyme and amyloid precursor protein (APP). <italic>Nucleosides Nucleotides Nucleic Acids</italic> 2020, 39: 905–922). In the same manner, the construction of expression vectors for AT and APP can be performed as shown in <xref ref-type="fig" rid="neurosci-09-02-010-g006">Figure 6</xref>. These expressions vectors, with or without GPI anchor, could be used as tools for (a) studying the effects of Arg393His mutation in AT; (b) studying the emerging role of Arg393His mutation in AT and cancer; (c) studying intermolecular interactions between APP and AT.</p> <p>Furthermore, the construction of expression vectors as described in Ref. #148, especially the one with GPI, can be used as a model for the construction of expression vectors for any protein targeting to the cell plasma membrane for studying intermolecular interactions and could be therefore useful in the vaccines as well as antiviral drugs development (studying intermolecular interactions between the spike glycoprotein of the severe acute respiratory syndrome coronavirus 2, SARS-CoV-2, as well as its variants and the angiotensin-converting enzyme 2, ACE2, in coronavirus disease 2019 (COVID-19) <xref ref-type="bibr" rid="b155">[155]</xref>,<xref ref-type="bibr" rid="b156">[156]</xref>, for example).</p> </abstract>

Analysis of complement system and its related factors in Alzheimer’s disease

“…Our study identified several complement system-related genes in AD. Among the 23 genes previous studies have shown their correlation with AD, we have: GFAP [ 41 , 42 ], PDGFRβ [ 43 – 45 ], NFKBIA [ 46 ], TNFRSF1B [ 47 ], NOTCH1 [ 48 ], BCL6 [ 49 ], CSF1R [ 50 ], LEP [ 51 ], DCLRE1C [ 52 ], KCNJ10 [ 53 ], MAP2K1 [ 54 ], VIP [ 55 ], SNCA [ 56 ], ENO2 [ 57 ], SST [ 58 ], UCHL1 [ 59 ], HPRT1 [ 60 ], STAT4 [ 61 ], CD14 [ 62 ], ITGB2 [ 63 ], SPP1 [ 64 ], STX1A [ 65 ], and SYP [ 66 ]. And these genes are involved in the regulation of molecules associated with the complement system, for instance, GFAP [ 67 ], PDGFRβ [ 68 ], NFKBIA [ 69 ], TNFRSF1B [ 70 ], NOTCH1 [ 71 ], BCL6 [ 72 ], CSF1R [ 73 ], LEP [ 74 ], DCLRE1C [ 75 ], KCNJ10 [ 76 ], MAP2K1 [ 77 ], VIP [ 78 ], SNCA [ 79 ], ENO2 [ 80 ], SST [ 81 ], UCHL1 [ 82 ], HPRT1 [ 83 ], STAT4 [ 84 ], CD14 [ 85 ], ITGB2 [ 86 ], SPP1 [ 87 ], STX1A [ 88 ], and SYP [ 89 ].…”